Blog

Company News

Industry Trends

Laws Regulations

All Categories >

21

2025-01

Hycells’s 2025 Annual Celebration Concludes Successfully | Reflecting on the Past, Ushering in a New Beginning

On January 17, 2025, the 2025 Heyou Annual Gala, themed “Reflecting on the Past, Ushering in a New Beginning,” was held as scheduled.

2025-01-21

He Yousheng

21

2025-01

New Start in 2025 | Shanghai Hycells Biotechnology and Shandong Qidu Biotechnology Sign Strategic Cooperation Agreement

On January 18, 2025, Shanghai Hycells Biotechnology and Shandong Qidu Biotechnology signed a strategic cooperation agreement to jointly pursue product development initiatives. Since its establishment, Hycells has been committed to providing customers with end-to-end solutions encompassing the R&D, manufacturing, sales, and service of primary immune cell products. The company boasts cutting-edge biotechnology and a robust R&D team, leveraging its cell bank and culture media R&D platform to offer a comprehensive suite of customized services for immune cells, stem cells, and related cell culture media.

2025-01-21

He Yousheng

16

2025-01

Hycells Spring Festival Holiday Notice

We extend our heartfelt gratitude to every one of our valued clients—your unwavering trust and support have enabled Hycells to advance steadily in the industry and gradually rise to prominence. We also thank each and every member of the Hycells team for your hard work and outstanding contributions; it is your dedication and perseverance that have laid a solid foundation for the company’s continued growth. To ensure that everyone can get adequate rest and spend quality time with their families,

2025-01-16

He Yousheng

09

2025-01

Stem Cell Drug Compliance Services | MSC One-Stop Comprehensive Solution

On January 2, 2025, the National Medical Products Administration granted conditional approval, via the priority review and approval pathway, for the launch of China’s first stem cell–based therapeutic product, amivastin injection, for the treatment of acute graft-versus-host disease (aGVHD) in patients aged 14 years and older whose condition is primarily characterized by gastrointestinal involvement and who have failed conventional corticosteroid therapy. Amivastin injection is the first mesenchymal stem cell (MSC)–based therapeutic product approved for marketing in China for the treatment of aGVHD refractory to corticosteroid therapy. To date, approximately ten MSC–based therapies have been approved globally, with variations in cell source and indications. The past year is poised to be a landmark chapter in the history of stem cell therapy in China, as the wheels of fate begin to turn.

2025-01-09

He Yousheng

29

2024-11

Only by Joining Hands Can We Go Far | We Cordially Invite You to Participate in the Distrimap Conference on Innovation and Development of Research Tools and Distribution Channels

The Distrimap Conference on Innovation in Research Tool Development and Distribution Channels, hosted by the Juyuan Platform and co-organized by Dingxiangtong, Aniu Youshuo, Kasma Platform, and Instrument Learning Network, will kick off on December 7. At this event, more than 40 industry leaders will deliver in-depth market analyses from their respective areas of expertise, providing a comprehensive overview of industry prospects, customer pain points, cutting-edge products, technological trends, service support, and investment attraction policies. Hycells has also been invited to attend the conference.

2024-11-29

He Yousheng

20

2024-11

Hycells New Product | Ultra-High-Density MSC Serum-Free Culture Medium

Mesenchymal stem cells (MSCs) are multipotent stem cells that possess all the hallmark properties of stem cells: self-renewal and the capacity for multi-lineage differentiation. MSCs were first identified in bone marrow, and subsequent studies have revealed their presence in numerous tissues throughout human development. Currently, MSCs can be isolated and cultured from a variety of sources, including bone marrow, adipose tissue, synovial membrane, bone, muscle, lung, liver, pancreas, as well as amniotic fluid and umbilical cord blood; among these, bone-marrow–derived MSCs are the most widely used.

2024-11-20

He Yousheng
< 1...91011...18 >